Skip to main content
NCBI home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2009 Apr 7;32(4):220–225. doi: 10.1002/clc.20345

The Importance of Gamma‐Glutamyltransferase Activity in Patients with Coronary Artery Disease

Sabri Demircan 1,✉, Mustafa Yazici 1, Kenan Durna 1, Fethi Kilicaslan 2, Serdar Demir 1, Mesut Pinar 1, Okan Gulel 1
PMCID: PMC6652977  PMID: 19353699

Abstract

Background

In this study, we sought to investigate the relation of gamma‐glutamyltransferase (GGT) levels with the significance of coronary artery disease (CAD), clinical presentation, left ventricular (LV) function, and inflammatory activity.

Methods

A total of 235 patients (mean age: 60.1 ± 10.5 years, 166 [70%] males) who had coronary angiography were included in the study. Patients who had CAD constituted the study group (Group 1, n=189) and patients who had insignificant coronary disease or normal coronary activity constituted the control group (Group 2, n=46).

Results

GGT levels were higher in Group 1 than Group 2 (38.7 ± 30.9 U/L versus 27.5 ± 17.5 U/L, p =0.025). Left ventricular ejection fraction (LVEF) was lower in Group 1 than Group 2 (52.6% ± 11.7% versus 58.8% ± 11.3%, p < 0.002). GGT activity (40.2 ± 32.5 U/L versus 29.1 ± 18.3 U/L, p < 0.002) and c‐reactive protein (CRP) levels (33.9 ± 43.6 mg/dl versus 17.8 ± 29.8 mg/dl, p < 0.002) were higher, LVEF (52.6% ± 12.1% versus 56.5% ± 11.0%, p =0.021) was lower in patients with acute coronary syndrome compared with stable CAD group. In regression analysis, CRP levels (p < 0.0001, odds ratio [OR]=3.77, 95% confidence interval [CI] 0.10 < OR < 0.32), LVEF (p =0.016, OR=− 2.44, 95% CI − 0.95 < OR < − 0.10) and LV end‐diastolic pressure (p =0.015, OR=4.31, 95% CI − 1.19 < OR < − 0.13) were independent predictors of GGT activity.

Conclusions

The increased GGT activity is related to LV function, clinical stability, and inflammatory activity rather than the severity of CAD. Measurement of GGT activity may be useful in predicting cardiovascular risk. Copyright © 2009 Wiley Periodicals, Inc.

Full Text

The Full Text of this article is available as a PDF (379.0 KB).

References

  • 1. Whitfield JB. Gamma glutamyl transferase. Crit Rev Clin Lab Sci. 2001; 38: 263–355. [DOI] [PubMed] [Google Scholar]
  • 2. Emdin M, Pompella A, Paolicchi A. Gamma‐glutamyltransferase, atherosclerosis, and cardiovascular disease: Triggering oxidative stress within the plaque. Circulation. 2005; 112: 2078–2080. [DOI] [PubMed] [Google Scholar]
  • 3. Paolicchi A, Emdin M, Ghliozeni E, Ciancia E, Passino C, et al. Atherosclerotic plaques contain gamma‐glutamyl transpeptidase activity. Circulation. 2004; 109: 1140. [DOI] [PubMed] [Google Scholar]
  • 4. Lee DH, Jacobs DR Jr, Gross M, Kiefe CI, Roseman J, et al. Gamma‐glutamyltransferase is a predictor of incident diabetes and hypertension: The Coronary Artery Risk Development in Young Adults (CARDIA) Study. Clin Chem. 2003; 49: 1358–1366. [DOI] [PubMed] [Google Scholar]
  • 5. Lee DH, Silventoinen K, Hu G, Jacobs DR Jr, Jousilahti P, et al. Serum gamma‐glutamyltransferase predicts non‐fatal myocardial infarction and fatal coronary heart disease among 28,838 middle‐aged men and women. Eur Heart J. 2006; 27: 2170–2176. [DOI] [PubMed] [Google Scholar]
  • 6. Wannamethee G, Ebrahim S, Shaper AG. Gamma‐glutamyltransferase: determinants and association with mortality from ischemic heart disease and all causes. Am J Epidemiol. 1995; 142: 699–708. [DOI] [PubMed] [Google Scholar]
  • 7. Pompella A, Emdin M, Passino C, Paolicchi A. The significance of serum γ‐glutamyltransferase in cardiovascular diseases. Clin Chem Lab Med. 2004; 42: 1085–1091. [DOI] [PubMed] [Google Scholar]
  • 8. Persijn JP, van der Slik W. A new method for the determination of gamma glutamyltransferase in serum. J Clin Chem Clin Biochem. 1976; 14: 421–427. [DOI] [PubMed] [Google Scholar]
  • 9. Teicholz LE, Kreulen T, Herman MV, Gorlin R. Problems in echocardiographic volume determinations: Echocardiographic‐angiographic correlations in the presence or absence of asynergy. Am J Cardiol. 1976; 37: 7–11. [DOI] [PubMed] [Google Scholar]
  • 10. Bo S, Gambino R, Durazzo M, Guidi S, Tiozzo E, et al. Associations between gamma‐glutamyl transferase, metabolic abnormalities and inflammation in healthy subjects from a population‐based cohort: A possible implication for oxidative stress. World J Gastroenterol. 2005; 11: 7109–7117. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Rahman I, MacNee W. Oxidative stress and regulation of glutathione in lung inflammation. Eur Respir J. 2000; 16: 534–554. [DOI] [PubMed] [Google Scholar]
  • 12. Karp DR, Shimooku K, Lipsky PE. Expression of gamma‐glutamyl transpeptidase protects ramos B cells from oxidation‐induced cell death. J Biol Chem. 2001; 276: 3798–3804. [DOI] [PubMed] [Google Scholar]
  • 13. Paolicchi A, Minotti G, Tonarelli P, Tongiani R, De Cesare D, et al. Gamma‐glutamyl transpeptidase‐dependent iron reduction and LDL oxidation—a potential mechanism in atherosclerosis. J Investig Med. 1999; 47: 151–160. [PubMed] [Google Scholar]
  • 14. Ulus T, Yildirir A, Demirtas S, Demir O, Sade LE, et al. Serum gamma‐glutamyl transferase activity: A new marker for stent restenosis? Atherosclerosis. 2007; 195: 348–353. [DOI] [PubMed] [Google Scholar]
  • 15. Onat A, Hergenc G, Karabulut A, Turkmen S, Dogan Y, et al. Serum gamma glutamyltransferase as a marker of metabolic syndrome and coronary disease likelihood in nondiabetic middle‐aged and elderly adults. Prev Med. 2006; 43: 136–139. [DOI] [PubMed] [Google Scholar]
  • 16. Ruttmann E, Brant LJ, Concin H, Diem G, Vorarlberg Health Monitoring and Promotion Program Study Group , et al. Gamma‐glutamyltransferase as a risk factor for cardiovascular disease mortality: An epidemiological investigation in a cohort of 163,944 Austrian adults. Circulation. 2005; 112: 2130–2137. [DOI] [PubMed] [Google Scholar]
  • 17. Emdin M, Passino C, Michelassi C, Titta F, L'abbate A, et al. Prognostic value of serum gamma‐glutamyl transferase activity after myocardial infarction. Eur Heart J. 2001; 22: 1802–1807. [DOI] [PubMed] [Google Scholar]
  • 18. Lee DH, Jacobs DR Jr. Association between serum gammaglutamyltransferase and C‐reactive protein. Atherosclerosis. 2005; 178: 327–330. [DOI] [PubMed] [Google Scholar]
  • 19. Jean JC, Liu Y, Brown LA, Marc RE, Klings E, et al. Gamma‐glutamyl transferase deficiency results in lung oxidant stress in normoxia. Am J Physiol Lung Cell Mol Physiol. 2002; 283: L766–L776. [DOI] [PubMed] [Google Scholar]
  • 20. Joyce‐Brady M, Takahashi Y, Oakes SM, Rishi AK, Levine RA, et al. Synthesis and release of amphipathic gamma‐glutamyl transferase by the pulmonary alveolar type 2 cell: Its redistribution throughout the gas exchange portion of the lung indicates a new role for surfactant. J Biol Chem. 1994; 269:14219–14226. [PubMed] [Google Scholar]
  • 21. Emdin M, Passino C, Donato L, Paolicchi A, Pompella A. Serum gamma‐glutamyltransferase as a risk factor of ischemic stroke might be independent of alcohol consumption. Stroke. 2002; 33: 1163–1164. [DOI] [PubMed] [Google Scholar]
  • 22. Rosenblat M, Aviram M. Macrophage glutathione content and glutathione peroxidase activity are inversely related to cell‐mediated oxidation of LDL: In vitro and in vivo studies. Free Radic Biol Med. 1998; 24: 305–317. [DOI] [PubMed] [Google Scholar]
  • 23. Lee RT, Libby P. The unstable atheroma. Arterioscler Thromb Vasc Biol. 1997; 17: 1859–1867. [DOI] [PubMed] [Google Scholar]
  • 24. Berliner JA, Heinecke JW. The role of oxidized lipoproteins in atherogenesis. Free Radic Biol Med. 1996; 20: 707–727. [DOI] [PubMed] [Google Scholar]
  • 25. Nilssen O, Forde OH. Seven‐year longitudinal population study of change in gamma‐glutamyltransferase: The Tromso Study. Am J Epidemiol. 1994; 139: 787–792. [DOI] [PubMed] [Google Scholar]
  • 26. Lee DS, Evans JC, Robins SJ, Wilson PW, Albano I, et al. Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: The Framingham Heart Study. Arterioscler Thromb Vasc Biol. 2007; 27: 127–133. [DOI] [PubMed] [Google Scholar]
  • 27. Ridker PM, Wilson PW, Grundy SM. Should C‐reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation. 2004; 109: 2818–2825. [DOI] [PubMed] [Google Scholar]
  • 28. Ross R. Atherosclerosis: An inflammatory disease. N Engl J Med. 1999; 340: 115–126. [DOI] [PubMed] [Google Scholar]
  • 29. Koenig W, Sund M, Fröhlich M, Fischer HG, Löwel H, et al. C‐reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle‐aged men: Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation. 1999; 99: 237–242. [DOI] [PubMed] [Google Scholar]
  • 30. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, et al. Low grade inflammation and coronary heart disease: Prospective study and updated meta‐analyses. BMJ. 2000; 321: 199–204. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31. Saijo Y, Utsugi M, Yoshioka E, Horikawa N, Sato T, et al. The relationship of gamma‐glutamyltransferase to C‐reactive protein and arterial stiffness. Nutr Metab Cardiovasc Dis. 2008; 185: 214–218. [DOI] [PubMed] [Google Scholar]
  • 32. Pleiner J, Mittermayer F, Schaller G, Marsik C, MacAllister RJ, et al. Inflammation‐induced vasoconstrictor hyporeactivity is caused by oxidative stress. J Am Coll Cardiol. 2003; 42: 1656–1662. [DOI] [PubMed] [Google Scholar]
  • 33. Hill MF, Singal PK. Antioxidant and oxidative stress changes during heart failure subsequent to myocardial infarction in rats. Am J Pathol. 1996; 148: 291–300. [PMC free article] [PubMed] [Google Scholar]
  • 34. Sawyer DB, Siwik DA, Xiao L, Pimentel DR, Singh K, et al. Role of oxidative stress in myocardial hypertrophy and failure. J Mol Cell Cardiol. 2002; 34: 379–388. [DOI] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES